Search Videos and More
Video
ESMO25 Breast Cancer Highlights: DESTINY-Breast11 & DESTINY-Breast05
Harold Burstein, MD, PhD, and Guilherme Nader Marta, MD, discuss the DESTINY-Breast11 and DESTINY-Breast05 trials examining trastuzumab deruxtecan in HER2-positive breast cancer.
Video
ESMO25 Breast Cancer Highlights: ASCENT-03 and TROPION-Breast02
Harold Burstein, MD, PhD, and Ana Garrido- Castro, MD, discuss the ASCENT-03 and TROPION-Breast02 trials, investigating antibody-drug conjugates for triple-negative breast cancer.
Video
ESMO25 Breast Cancer Highlights: Antibody-Drug Conjugates
Harold Burstein, MD, PhD, and Ilana Schlam, MD, MPH, discuss OptiTROP-Breast02 and other trials investigating antibody-drug conjugates (ADCs).
News
Dana-Farber Research Opens the Door to Finding More Effective Treatments for Ewing Sarcoma
In 2014, Dana-Farber pediatric oncologist Brian Crompton, MD, discovered that a gene called STAG2 is mutated in about 15 percent of patients with Ewing sarcoma, a form of bone cancer that largely occurs in children and adolescents.
News
Dana-Farber Research Supports FDA Approval of Sevabertinib for HER2-Mutant Lung Cancer
The US Food and Drug Administration has approved sevabertinib, an oral targeted therapy for adult patients with non-small-cell lung cancer (NSCLC) whose tumors harbor certain HER2 (also called ERBB2) mutations and who have previously received chemotherapy or immunotherapy.
Video
2025 ESMO Bladder Cancer Highlights
The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the bladder cancer clinical updates you need to know from ESMO 2025.
Video
2025 ESMO Prostate Cancer Highlights
The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the prostate cancer clinical updates you need to know from ESMO 2025
Video
2025 ESMO Kidney Cancer Highlights
The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the kidney cancer clinical updates you need to know from ESMO 2025.
News
Dana-Farber Research News 11.15.2025
This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from October 16 - October 31.
Symposium
ESMO Congress 2025
Review video summaries and research highlights from Dana-Farber Faculty, presented at ESMO Congress 2025.
News
Dana-Farber Cancer Institute Faculty Among World's Most Highly Cited Researchers
Dana-Farber Cancer Institute is proud to announce that 38 of its researchers have been named to the Highly Cited Researchers list of 2025, released by the Institute for Scientific Information at Clarivate.
News
Dana-Farber Research Points to Potential Gene Therapy Improvements
Viruses aren’t thought of as living beings. Rather, they are collections of genetic instructions that hijack the replication machinery of living cells to perpetuate themselves.